FO
HRTX icon

FT Options’s Heron Therapeutics HRTX Stock Holding History

FT Options’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-30,000
Closed -$41K – 302
2016
Q3 		$41K Buy
+30,000
New +$557K 0.03% 229
2016
Q2 		– Sell
-2,500
Closed -$7K – 376
2016
Q1 		$7K Buy
+2,500
New +$49.3K 0.01% 256

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM

FT Options's HRTX Position: Q4 2016 in Review

FT Options sold out of Heron Therapeutics (HRTX) in Q4 2016, closing a stake of 29,937 shares — an estimated $516K sold.

FT Options first reported a position in HRTX in Q4 2015 and held it in 3 quarters. The position peaked at $1.9M in Q4 2015. 99 funds tracked by Wall St. Rank hold HRTX as of Q4 2016.

  • FT Options reported no remaining Heron Therapeutics position as of Q4 2016 after selling out during the quarter.
  • FT Options sold 29,937 Heron Therapeutics shares in Q4 2016, an estimated $516K.
  • FT Options first reported a position in Heron Therapeutics in Q4 2015 and held it in 3 quarters.
  • FT Options's Heron Therapeutics position peaked at $1.9M in Q4 2015.
  • 99 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2016.

Based on FT Options's 13F filing for Q4 2016, filed 10 Feb 2017.